10-Q: Ardelyx Q3 2025: IBSRELA Soars, XPHOZAH Dips Amid Policy Shift

Ardelyx reports increased total revenue driven by strong IBSRELA sales and milestone payments, but faces a larger net loss and significant XPHOZAH sales decline due to Medicare Part D changes.

Summary

• Net loss increased to $61.2 million for the nine months ended September 30, 2025, compared to $43.8 million in the prior year.
• Total revenues grew by 30% to $282.1 million for the nine months ended September 30, 2025, up from $217.5 million in 2024.
• IBSRELA net product sales surged by 80% to $187.6 million for the nine months ended September 30, 2025, compared to $104.4 million in 2024.
• XPHOZAH net product sales decreased by 27% to $75.8 million for the nine months ended September 30, 2025, from $103.7 million in 2024, primarily due to the loss of Medicare Part D reimbursement effective January 1, 2025.
• Licensing revenue significantly increased to $5.1 million, including a $5.0 million milestone from Fosun Pharma for tenapanor approval in China.
• Non-cash royalty revenue rose by 305% to $7.2 million, including a $3.4 million commercialization milestone from Kyowa Kirin for PHOZEVEL sales in Japan.
• Operating expenses increased by 35% to $299.5 million, driven by higher commercialization, administrative, and R&D costs.
• Cash and cash equivalents decreased to $42.7 million as of September 30, 2025, from $64.9 million at December 31, 2024.
• Long-term debt increased to $202.1 million, following a $50.0 million draw of the Term E Loan in June 2025.
• Ardelyx initiated a development program for RDX10531, a next-generation NHE3 inhibitor, with an IND submission planned for 2026.
• Several executive leadership changes were announced, including a new Chief Financial Officer, Chief Medical Officer, and Chief Technical Operations Officer, and the separation of the former Chief Financial and Operations Officer.

Sentiment

Score: 5

Explanation: While IBSRELA sales show strong growth and the company is making strategic moves in leadership and pipeline development, the significant decline in XPHOZAH sales due to policy changes and the increased net loss present considerable headwinds and financial uncertainty. The company's liquidity has decreased, and it anticipates needing additional financing, balancing the positive operational momentum with financial challenges and regulatory risks.

Positives

• IBSRELA net product sales increased by 80% to $187.6 million for the nine months ended September 30, 2025, reflecting higher demand and net price.
• Total revenues increased by 30% to $282.1 million for the nine months ended September 30, 2025.
• Received a $5.0 million licensing milestone from Fosun Pharma for tenapanor approval in China.
• Earned a $3.4 million commercialization milestone from Kyowa Kirin for PHOZEVEL sales in Japan.
• Fully recognized and remitted the $75.0 million royalty obligation under the AstraZeneca Termination Agreement as of Q2 2025, reducing future 'other cost of revenue'.
• Initiated a development program for RDX10531, a next-generation NHE3 inhibitor, indicating pipeline expansion.
• Strengthened executive leadership with new hires for Chief Financial Officer, Chief Medical Officer, and Chief Technical Operations Officer.
• Dismissal of the Go and Morris shareholder derivative lawsuits on April 30, 2025.

Negatives

• Net loss increased to $61.2 million for the nine months ended September 30, 2025, compared to $43.8 million in the prior year.
• XPHOZAH net product sales decreased by 27% to $75.8 million for the nine months ended September 30, 2025, primarily due to the loss of Medicare Part D reimbursement.
• Operating expenses increased significantly by 35% to $299.5 million for the nine months ended September 30, 2025.
• Cash and cash equivalents decreased by 34% to $42.7 million as of September 30, 2025, from $64.9 million at December 31, 2024.
• Long-term debt increased to $202.1 million, with additional committed senior secured term loans available for draw.
• The inclusion of XPHOZAH in the ESRD PPS effective January 1, 2025, negatively and materially impacts revenue from XPHOZAH sales for Medicare beneficiaries.
• Ongoing legal proceedings, including a lawsuit against CMS regarding XPHOZAH reimbursement and a securities class action (Yarborough Action).

Risks

• Inability to achieve or sustain cash flow positivity due to losses incurred since inception and potential future losses if revenue growth is insufficient or new business opportunities are pursued.
• Requirement for additional financing for the foreseeable future to invest in IBSRELA and XPHOZAH growth and pipeline development, with the risk of inability to access necessary capital on acceptable terms.
• Substantial dependence on the successful commercialization of IBSRELA, with no guarantee of maintaining market acceptance, growing market share, or securing adequate coverage and reimbursement.
• Uncertainty regarding sufficient market acceptance, adequate coverage, and reimbursement for XPHOZAH, exacerbated by its inclusion in the ESRD PPS.
• Negative and material impact on XPHOZAH revenue due to its inclusion in the ESRD PPS, eliminating Medicare Part D coverage for Medicare beneficiaries as of January 1, 2025.
• Potential adverse effects from current and future healthcare reform legislation, regulation, or actions by the Trump Administration, which may increase commercialization costs and negatively impact product prices.
• Risk of undesirable side effects or other properties of IBSRELA and/or XPHOZAH limiting commercial success, potentially leading to regulatory actions, recalls, or lawsuits.
• Uncertainty of third-party payor coverage and reimbursement status for newly commercialized products, with failure to obtain or maintain adequate coverage limiting marketability and revenue generation.
• Complete reliance on third parties, including single-source suppliers, for manufacturing IBSRELA and XPHOZAH, posing risks of non-compliance, raw material shortages, or manufacturing difficulties.
• Restrictions on operating activities due to covenants under the loan and security agreement with SLR, with potential requirement to repay outstanding indebtedness in an event of default.
• Substantial competition from other biotechnology and pharmaceutical companies, potentially leading to faster or more successful product development and commercialization by competitors.
• Difficulties in managing current activities and growth given the level of managerial, operational, financial, and other resources.
• Risks associated with strategic transactions, such as acquisitions or in-licensing, including increased expenses, integration challenges, and diversion of management attention.
• Inherent risk of product liability lawsuits, which could result in substantial liabilities and require limiting commercialization.
• Challenges in attracting, retaining, and motivating executives, senior management, and key personnel.
• Risks related to compliance with data protection, privacy, and security laws, including potential for security breaches and regulatory enforcement actions.
• Dependence on information technology systems, with risks of security breaches, data loss, and other disruptions.
• Potential for adverse effects from earthquakes or other natural disasters, as business continuity and disaster recovery plans may be inadequate.
• Ongoing regulatory obligations and review for approved products, with risks of significant additional expense, restrictions, or market withdrawal.
• Disruptions at the U.S. FDA and other government agencies hindering timely review and processing of regulatory submissions.
• Risks of non-compliance with U.S. FDA and other regulations related to product promotion for unapproved uses, sales practices, and patient assistance programs.
• Risk of employees, contractors, and partners engaging in misconduct or improper activities, including noncompliance with regulatory standards.
• Challenges in obtaining regulatory approvals in foreign jurisdictions, which could prevent international marketing.
• Risks of non-compliance with healthcare laws, regulation, and enforcement, including federal Anti-Kickback Statute and False Claims Act.
• Potential for legislative or regulatory healthcare reforms in the U.S. to increase difficulty and cost of obtaining regulatory approval and marketing products.
• Risks of non-compliance with reporting and payment obligations under the Medicaid Drug Rebate Program (MDRP) and other governmental pricing programs.
• Challenges in obtaining, maintaining, and protecting intellectual property rights, including patents, trademarks, and trade secrets.
• Exposure to third-party claims alleging infringement, misappropriation, or violation of intellectual property rights.
• Inability to enforce intellectual property rights globally, particularly in countries with weaker protections.
• Volatility of common stock price due to various factors, including commercialization success, regulatory actions, and competition.
• Potential for immediate dilution if additional shares of common stock are sold in future financings.
• Significant costs and management time devoted to operating as a public company and complying with regulations like Section 404 of Sarbanes-Oxley.
• Adverse effects from the global economic environment, including inflation and rising interest rates.
• Provisions in charter documents and Delaware law that could discourage takeovers.
• Claims for indemnification by directors and officers reducing available funds.
• No current intention to pay dividends, making stock appreciation the sole return on investment.

Future Outlook

The company expects to increasingly rely on cash generated from operations but anticipates requiring significant additional capital to fund its operating plan and pipeline investments. It plans to submit an Investigational New Drug (IND) application for RDX10531 in 2026. The impact of the Inflation Reduction Act and potential policies from the Trump administration on drug pricing is uncertain but likely to be significant for the pharmaceutical industry.

Management Comments

• We are committed to our mission of discovering, developing and commercializing first-in-class medicines that address unmet patient needs.
• Our principal strategy is to maintain our commercial momentum with our current products while identifying additional assets that leverage our core capabilities, including clinical, developmental and regulatory expertise and commercial excellence while maintaining a solid financial foundation, to support our future growth.
• Our priorities include: (i) accelerating IBSRELA growth momentum; (ii) executing our XPHOZAH strategy to grow utilization; (iii) building a pipeline focused on areas of unmet patient need; and (iv) continuing to deliver strong commercial and financial performance.
• We believe our available cash, cash equivalents and short-term investments as of September 30, 2025 will be sufficient to fund our planned operations for at least a period of one year from the issuance of these financial statements.

Industry Context

The biopharmaceutical industry is highly competitive, characterized by substantial R&D and commercialization costs. Regulatory changes, such as the inclusion of XPHOZAH in the ESRD PPS and the Inflation Reduction Act, are creating significant pricing and reimbursement pressures, particularly for new drugs and those covered by Medicare. The industry also faces increasing scrutiny over drug pricing and evolving data protection regulations. Ardelyx's focus on first-in-class medicines and pipeline expansion aligns with industry trends of seeking innovative solutions for unmet medical needs, while its challenges with XPHOZAH reimbursement reflect broader industry-wide pressures from payors and government policies.

Comparison to Industry Standards

• The significant increase in IBSRELA sales (80% year-over-year for nine months) indicates strong market penetration and acceptance, potentially outperforming some new drug launches in the gastroenterology space, though direct comparable company data is not provided in the filing.
• The 27% decline in XPHOZAH sales due to Medicare Part D changes highlights the substantial impact of policy shifts on pharmaceutical products, a risk factor common across the industry, particularly for drugs targeting Medicare beneficiaries. This situation is comparable to other oral-only drugs for ESRD patients on dialysis without injectable or intravenous equivalents that were also transitioned into the ESRD PPS.
• The company's accumulated deficit of $946.5 million and continued net losses are common for biopharmaceutical companies in development and early commercialization phases, especially those investing heavily in R&D and commercial infrastructure.
• The increase in R&D and SG&A expenses (26% and 37% respectively for nine months) is consistent with a company actively commercializing two products and investing in pipeline expansion, aligning with industry benchmarks for growth-stage biotechs.
• The company's reliance on third-party manufacturers and single-source suppliers is a common industry practice but also a recognized risk, as highlighted in the filing, similar to many smaller to mid-sized biopharma companies.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit against CMS (American Association of Kidney Patients and National Minority Quality Forum v. CMS) claiming violation of statutory and regulatory authority by including XPHOZAH in the ESRD PPS. Motion to Dismiss granted, appeal filed, oral argument heard on September 25, 2025.
• Yarborough v. Ardelyx, Inc., et al. (securities class action) alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 related to the decision not to file for Transitional Drug Add-on Payment Adjustment for XPHOZAH. Defendants filed a motion to dismiss on March 14, 2025.
• In re Ardelyx, Inc. Stockholder Derivative Litigation (consolidated derivative actions) alleging violations of Sections 10(b) and/or 14(a) of the Exchange Act, breaches of fiduciary duty, unjust enrichment, waste, and aiding and abetting breaches of fiduciary duty, based on similar allegations as the Yarborough Action. Stayed pending resolution of the Yarborough Action.
• Go v. Raab, et al. and Morris v. Raab, et al. (shareholder derivative lawsuits) alleging violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties, etc., were dismissed on April 30, 2025.

Stakeholder Impact

• Shareholders: Increased net loss and decreased XPHOZAH sales could negatively impact share price. Dilution risk from potential future equity raises. Strong IBSRELA growth and pipeline development offer long-term potential. Legal proceedings create uncertainty.
• Employees: Executive leadership changes, new hires, and ongoing stock-based compensation plans.
• Customers (Patients): XPHOZAH access and affordability impacted by Medicare Part D changes. Continued availability of IBSRELA and XPHOZAH. Development of RDX10531 for future therapeutic options.
• Payors: Ongoing legal challenge against CMS regarding XPHOZAH reimbursement highlights tension over drug pricing and coverage.
• Suppliers/CMOs: Continued reliance on third-party manufacturers, including single-source suppliers, for product supply.

Next Steps

• Accelerate IBSRELA growth momentum.
• Execute XPHOZAH strategy to grow utilization.
• Build a pipeline focused on areas of unmet patient need.
• Continue to deliver strong commercial and financial performance.
• Submit an Investigational New Drug (IND) application for RDX10531 in 2026.
• Justin Renz's employment will end on the Separation Date (earliest of Dec 31, 2025, or 30 days after new CFO starts, or voluntary resignation/cause).
• Sue Hohenleitner to commence employment as Chief Financial Officer on October 13, 2025.
• Edward Conner, M.D. commenced employment as Chief Medical Officer on August 7, 2025.
• John E. Bishop, Ph.D., MBA commenced employment as Chief Technical Operations Officer on July 1, 2025.
• Ongoing appeal in the lawsuit against CMS regarding XPHOZAH inclusion in ESRD PPS.

Key Dates

Recommendation

Ardelyx presents a mixed financial picture with strong growth in IBSRELA sales offset by a significant decline in XPHOZAH revenue due to adverse Medicare Part D policy changes, leading to an increased net loss. While the company is actively strengthening its leadership team and pipeline with new drug candidates, substantial risks remain, particularly concerning XPHOZAH's commercial opportunity and ongoing legal challenges. The need for future financing and the inherent volatility of the biopharmaceutical sector suggest a cautious approach. Investors should monitor the resolution of XPHOZAH's reimbursement issues and the progress of pipeline development before making further investment decisions.

Keywords

Ardelyx, ARDX, IBSRELA, XPHOZAH, tenapanor, biopharmaceutical, IBS-C, hyperphosphatemia, CKD, dialysis, SEC filing, 10-Q, financial results, revenue, net loss, product sales, Medicare Part D, ESRD PPS, RDX10531, pipeline, Chief Financial Officer, Chief Medical Officer, Chief Technical Operations Officer, executive changes, legal proceedings, intellectual property, risk factors, corporate governance, capital raise